Transactions | |||
All | Buy | Sell | Option Exercise |
Filer's Name |
Relationship/ Title |
Trans. Date |
Trans. Type |
Ownership Type |
Security Type |
Shares |
Price |
Trans. Value |
Total Shares Owned |
Solomon Jonathan Eitan | Chief Executive Officer | 04/14/2025 | AA | Direct | COM | 126,748 | $0.00 | $0.00 | 126,748 |
Bassan Merav | Chief Development Officer | 04/14/2025 | AA | Direct | COM | 79,597 | $0.00 | $0.00 | 79,597 |
Wolfson Marina | Chief Financial Officer | 04/14/2025 | AA | Direct | COM | 68,545 | $0.00 | $0.00 | 68,545 |
Flynn James E | Director | 02/27/2025 | AM | Indirect | COM | 353,249 | $0.93 | $328,733.52 | 1,247,054 |
Flynn James E | Director | 02/27/2025 | AM | Indirect | COM | 353,249 | $0.93 | $328,733.52 | 1,247,054 |
Oron Assaf | Chief Business Officer | 09/16/2024 | AA | Direct | COM | 25,804 | $0.00 | $0.00 | 25,804 |
Solomon Jonathan Eitan | Chief Executive Officer | 09/16/2024 | AA | Direct | COM | 50,556 | $0.00 | $0.00 | 53,056 |
Bassan Merav | Chief Development Officer | 09/16/2024 | AA | Direct | COM | 31,749 | $0.00 | $0.00 | 31,749 |
Flynn James E | Director | 07/15/2024 | AM | Indirect | COM | 5,883,000 | $0.00 | $0.00 | 8,938,049 |
Flynn James E | Director | 07/15/2024 | AM | Indirect | COM | 5,883,000 | $0.00 | $0.00 | 8,938,049 |
Orbimed Israel Biofund Gp Limited Partnership | Other | 05/15/2024 | DS | Indirect | COM | 24,344 | $0.38 | $9,279.93 | 13,773,653 |
Orbimed Israel Biofund Gp Limited Partnership | Other | 05/15/2024 | AX | Indirect | COM | 9,280,408 | $0.24 | $2,264,419.55 | 13,797,997 |
Cystic Fibrosis Foundation | Other | 05/15/2024 | AX | Direct | COM | 4,778,265 | $0.00 | $4,778.27 | 9,330,580 |
Flynn James E | Director | 03/15/2024 | AA | Indirect | COM | 3,055,049 | $0.00 | $0.00 | 3,055,049 |
Flynn James E | Director | 03/15/2024 | AA | Indirect | COM | 3,055,049 | $0.00 | $0.00 | 3,055,049 |
Oron Assaf | Chief Business Officer | 11/29/2023 | DS | Direct | COM | 2,056 | $0.34 | $699.04 | 0 |
Oron Assaf | Chief Business Officer | 11/29/2023 | DS | Direct | COM | 3,414 | $0.35 | $1,194.90 | 2,056 |
Oron Assaf | Chief Business Officer | 11/29/2023 | DS | Direct | COM | 5,444 | $0.40 | $2,177.60 | 5,470 |
1   You are at page 1 of 1 pages |
Transaction Type Key First letter: A = Acquired, D = Disposed Second letter: A = Grant, award or other acquisition pursuant to Rule 16b-3(d) C = Conversion of derivative security | D = Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | E = Expiration of short derivative position | F = Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3. | G = Gift | H = Expiration (or cancellation) of long derivative position with value received | I = Discretionary transaction in accordance with Rule 16b-3(f) | J = Other | L = Small acquisition under Rule 16a-6 | M = Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | O = Exercise of out-of-the-money derivative security | P = Open market or private purchase | S = Open market or private sale | U = Disposition pursuant to a tender of shares in a change of control transaction | W = Acquisition or disposition by will or the laws of descent and distribution | X = Exercise of in-the-money or at-the-money derivative security | Z = Deposit into or withdrawal from voting trust |
![]() |
Send to Excel |